
This resource center is supported by an educational grant from Jazz Pharmaceuticals, Inc.
PER is proud to partner with the Cholangiocarcinoma Foundation & GI Cancers Alliance.
![]()
![]()
HER2 has emerged as an important target for a subgroup of upper GI cancers expressing high cell surface levels of the protein. Several treatment approaches have been approved for these cancers, necessitating careful selection of therapy based on individual patient characteristics and careful evaluation of the supporting evidence. This series of podcasts focuses on the role of HER2 testing and exploitation in biliary tract cancers and gastroesophageal adenocarcinomas, with emphasis on evidence supporting the use of novel therapeutics approaches for these patients, as well as management of the adverse events.

CE Activity Curriculum - Physician Credit
Resource Links
CE Activity Curriculum - Physician Credit
-
Free CE/CME
Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications
VideoRahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH
View Details -
Free CE/CME
Navigating the Adverse Event Landscape in HER2+ GEA Therapy
VideoRahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD
View Details -
Free CE/CME
The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data
VideoRahul Gosain, MD, MBA; Rohit Gosain, MD
View Details -
Free CE/CME
Decoding HER2 Alterations in GEA: Best Practices for Testing and Treatment
VideoRahul Gosain, MD, MBA; Rohit Gosain, MD; Rondell P. Graham, MBBS; Tanios S.…
View Details -
Free CE/CME
New Precision Strategies for HER2+ GEA: Interpreting New Data to Inform Clinical Practice
VideoRahul Gosain, MD, MBA; Rohit Gosain, MD; Sunnie Kim, MD; Samuel L. Cytryn, …
View Details
Resource Links
Safety and efficacy of anti-HER2 agents in the treatment of biliary tract cancers: A systematic review. – [https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.639]
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight [https://link.springer.com/article/10.1007/s40265-024-02132-2]
Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC [https://www.onclive.com/view/clinical-insights-incorporating-zanidatamab-and-other-her2-targeted-agents-into-the-real-world-practice-in-advanced-btc]
Managing Symptoms and Quality of Life During HER2-Targeted Therapy for Upper GI Cancer - [https://www.oncnursingnews.com/view/managing-symptoms-and-quality-of-life-during-her2-targeted-therapy-for-upper-gi-cancer]
10th Annual School of Gastrointestinal Oncology Archive – [https://www.gotoper.com/courses/10th-annual-school-of-gastrointestinal-oncology?sessionFields=%5B%5B%22profession%22%2C%22Physician%22%5D%5D]
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers [https://www.gotoper.com/courses/show-me-the-data-bridging-clinical-gaps-along-the-continuum-from-resectable-early-stage-to-advanced-gastricgastroesophageal-junction-cancers-ctzn?sessionFields=%5B%5B%22profession%22%2C%22Physician%22%5D%5D]